UK markets close in 6 hours 15 minutes
  • FTSE 100

    7,574.70
    +1.65 (+0.02%)
     
  • FTSE 250

    19,324.43
    +161.10 (+0.84%)
     
  • AIM

    849.16
    +0.57 (+0.07%)
     
  • GBP/EUR

    1.1621
    +0.0037 (+0.32%)
     
  • GBP/USD

    1.2143
    +0.0081 (+0.67%)
     
  • BTC-GBP

    14,094.01
    +119.64 (+0.86%)
     
  • CMC Crypto 200

    405.36
    +4.66 (+1.16%)
     
  • S&P 500

    4,080.11
    +122.48 (+3.09%)
     
  • DOW

    34,589.77
    +737.24 (+2.18%)
     
  • CRUDE OIL

    80.48
    -0.07 (-0.09%)
     
  • GOLD FUTURES

    1,792.30
    +32.40 (+1.84%)
     
  • NIKKEI 225

    28,226.08
    +257.09 (+0.92%)
     
  • HANG SENG

    18,736.44
    +139.21 (+0.75%)
     
  • DAX

    14,464.29
    +67.25 (+0.47%)
     
  • CAC 40

    6,743.72
    +5.17 (+0.08%)
     

RNA Based Therapeutics and Vaccines Market Report 2022-2032

ReportLinker
ReportLinker

Forecasts by Type (RNA Antisense Technologies, RNA Interference (RNAi) Technologies), by Application (Genetic Disorders (Spinal Muscular Atrophy, Cancer, Acute Hepatic Porphyria, Duchenne Muscular Dystrophy, Others), Autoimmune Disorders (Ophthalmology, Diabetes, Rheumatoid Arthritis, Others)), End-user (Research Institutes, Hospitals and Clinics) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis.

New York, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "RNA Based Therapeutics and Vaccines Market Report 2022-2032" - https://www.reportlinker.com/p06360741/?utm_source=GNW

The RNA Based Therapeutics and Vaccines Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or expand their existing operations in a new region.

CRISPR-based RNA Editing to Offer Lucrative Growth Prospects

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat) is an RNA-guided gene editing technique that inserts a double-strand break at a specific site in the genome using the Cas9 protein, which is obtained from bacteria. By using this technique, bacteria are able to seize brief nucleic acid sequences from invasive pathogens and mix them with the repeats in CRISPR loci. A group of bacterial endonucleases is directed by small RNAs generated by transcription of CRISPR loci to divide the genomes of invasive pathogens. This approach has gained acceptance as a potent method that makes genome editing possible in everyday life

Several new and existing DNA-editing companies have declared their ambition to expand into the RNA segment, and these include Boston, Massachusetts-based Beam Therapeutics, which has been researching CRISPR DNA editing as a treatment for several blood disorders. San Diego-based firm named Locana is also studying CRISPR-based RNA editing as a potential treatment for diseases like Huntington’s disease and motor-neuron disorder.

Numerous Development Potential of RNA-based Medicines

Since RNA-based therapies have the potential to cure both common and rare genetic illnesses, RNA-based therapies have attracted a lot of research. These types of studies are still in the pipeline, therefore businesses that commercialise these treatments first would have a competitive advantage over rivals. There are now just three commercially available RNA-based medicines based on antisense technology. Three ASO medicines have so far been approved by the FDA: nusinersen (Ionis Pharmaceuticals), eteplirsen (Sarepta Therapeutics), and inotersen (Ionis Pharmaceuticals and Akcea Therapeutics). As a result, there are numerous potential for the development and marketing of RNA-based medicines in the near future.

What Questions Should You Ask before Buying a Market Research Report?

• How is the RNA therapeutics market evolving?

• What is driving and restraining the RNA therapeutics market?

• How will each RNA therapeutics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?

• How will the market shares for each RNA therapeutics submarket develop from 2022 to 2032?

• What will be the main driver for the overall market from 2022 to 2032?

• Will leading RNA therapeutics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?

• Who are the leading players and what are their prospects over the forecast period?

• What are the RNA therapeutics projects for these leading companies?

• How will the industry evolve during the period between 2022 and 2032? What are the implications of

RNA therapeutics projects taking place now and over the next 10 years?

• Is there a greater need for product commercialization to further scale the RNA therapeutics market?

• Where is the RNA therapeutics market heading and how can you ensure you are at the forefront of the market?

• What are the best investment options for new product and service lines?

• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the RNA therapeutics market today, and over the next 10 years:

• Our 223-page report provides 96 tables and 146 charts/graphs exclusively to you.

• The report highlights key lucrative areas in the industry so you can target them – NOW.

• It contains in-depth analysis of global, regional and national sales and growth.

• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the RNA therapeutics market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.

• You will find original analyses, with business outlooks and developments.

• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Type

• RNA Antisense Technologies

• RNA Interference (RNAi) Technologies

Application

• Genetic Disorders

- Spinal Muscular Atrophy (SMA)

- Cancer

- Acute Hepatic Porphyria (AHP)

- Duchenne Muscular Dystrophy (DMD)

- Others

• Autoimmune Disorders

- Ophthalmology

- Oncology

- Diabetes

- Rheumatoid Arthritis (RA)

- Others

End-user

• Research Institutes

• Hospitals and Clinics

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America

• U.S.

• Canada

Europe

• Germany

• UK

• France

• Italy

• Spain

• Rest of Europe

Asia Pacific

• Japan

• China

• India

• Australia

• South Korea

• Rest of Asia Pacific

Latin America

• Brazil

• Mexico

• Rest of Latin America

MEA

• GCC

• South Africa

• Rest of MEA

The report also includes profiles and for some of the leading companies in the RNA Therapeutics Market, 2022 to 2032, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth

• Alnylam Pharmaceuticals, Inc.

• Arbutus Biopharma

• Arrowhead Pharmaceuticals, Inc.

• Benitec Biopharma

• Biogen

• Genzyme (Sanofi)

• Gradalis, Inc.

• Ionis Pharmaceuticals, Inc.

• Orna Therapeutics

• Sarepta Therapeutics, Inc.

• Silence Therapeutics

Overall world revenue for the RNA Therapeutics Market, 2022 to 2032 in terms of value the market will surpass US$6,992.1 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the RNA Therapeutics Market, 2022 to 2032 report help you?

In summary, our 210+ page report provides you with the following knowledge:

• Revenue forecasts to 2032 for RNA Therapeutics Market, 2022 to 2032 Market, with forecasts for type, application, and end-user each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2032 for five regional and 20 key national markets – See forecasts for the RNA Therapeutics Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 11 of the major companies involved in the RNA Therapeutics Market, 2022 to 2032.


Read the full report: https://www.reportlinker.com/p06360741/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001